Thought Leadership
Why Site And Partner Communications Are Critical To Autologous Cell Therapy Clinical Trials
Effective communication between clinical trial sites and partners is crucial for the […]
Read More....Time, Logistics, And Manufacturing In Autologous Cell Therapy Clinical Trials
Efficient time management, streamlined logistics, and standardized manufacturing processes are critical for […]
Read More....Clinical Research Considerations For Rare Disease Patients: Part 1 — Reinvigorate Patient Centricity
The article emphasizes the need for a shift towards patient-centric approaches in […]
Read More....Clinical Research Considerations For Rare Disease Patients: Part 2 — The Impact Of Physician And Site Support
Physician and site support are critical for the success of rare disease […]
Read More....The Write Side of AI: Helping Hands, Not Replacement Plans
The article explores the role of AI in medical writing, emphasizing that […]
Read More....Recovering A Clinical Trial That Has Been Derailed
When your asset is on the line, your partner of choice matters […]
Read More....High-Velocity Development: Gene Therapy Vs. Small Molecule
Gene therapy development operates at a high velocity compared to small molecule […]
Read More....Rare Disease Clinical Endpoints: Ingenuity Meets Practicality
Discover why the science that brought you to this point can only […]
Read More....CRAs Must Evolve Alongside Oncology Therapeutics
Clinical Research Associates (CRAs) must adapt to the evolving demands of oncology […]
Read More....FDA Update on ICH E6, E8, QbD and RBM in Clinical Trials
Integrating Quality by Design (QbD) and Risk-Based Monitoring (RBM) approaches in clinical […]
Read More....